NY-Z-CAPITAL-GROUP
6.2.2024 13:01:28 CET | Business Wire | Press release
Z Capital Group (“ZCG”) today announced it has signed as a Team Partner with Scuderia Ferrari for the 2024 Formula 1 season. The commitment will continue the successful partnership between ZCG and Scuderia Ferrari that began in 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131467963/en/
The 2023 partnership included numerous collaborative and innovative initiatives and, during the 2024 Formula 1 season, ZCG aims to work closely with Scuderia Ferrari to expand these initiatives and find new and creative ways to engage Formula 1 fans across the globe given ZCG’s international exposure.
Scuderia Ferrari will unveil its 2024 Formula 1 car on Tuesday, February 13, 2024. As a distinguished Team Partner, ZCG will prominently display its logo on the livery throughout the 2024 Formula 1 World Championship, starting at the Bahrain Grand Prix on March 2. In addition to the logo placement, this partnership includes broader collaboration and multifaceted engagement, underscoring a joint commitment to advancing success and growth for the partnership between Scuderia Ferrari and ZCG.
“We take great pride in our relationship and look forward to continuing our support of Scuderia Ferrari and building upon the success of our partnership in the 2023 season,” said James Zenni, Founder, President, and Chief Executive Officer of ZCG. “Ferrari consistently pushes the boundaries of innovation and global expansion. ZCG shares Scuderia Ferrari’s vision for excellence and strategic growth, and we eagerly anticipate further collaboration that can bring the experience and excitement of Formula 1 to more fans around the world.”
“We are pleased to renew our partnership with ZCG, with whom we share a passion for excellence and the desire to push the boundaries of innovation, without losing sight of the values and authority that stem from decades of experience in our respective fields,” said Lorenzo Giorgetti, Chief Racing Revenue Officer of Scuderia Ferrari. “We are keen to continue working with ZCG to reach an even wider audience with which to share the unique experience of Formula 1 and the very special world of Scuderia Ferrari.”
One of the most exciting and prestigious motorsport competitions in the world, Formula 1 has surged in popularity in recent years, particularly across the United States. U.S. television viewership doubled from 2018 to 2023, with an average of 1.11 million viewers per race during the 2023 season. ZCG remains committed to supporting the growth of Formula 1 through its partnership with Scuderia Ferrari, the most successful team in the history of this sport.
About ZCG
ZCG is an industry leader comprised of private markets asset management, business consulting services, technology development and solutions.
For almost 30 years, ZCG Principals have invested tens of billions in capital and have industry leading track records in private equity and credit.
ZCG has approximately $7B of AUM in asset management and its investors are some of the largest and most sophisticated global institutional investors including pension funds, endowments, foundations, sovereign wealth funds, central banks, and insurance companies.
ZCG has a global team comprised of over 400 professionals. For more information, please visit www.zcg.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131467963/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
